Your session is about to expire
← Back to Search
Other
Dextenza 0.4mg intracanalicular Insert for Cataract
Phase 4
Waitlist Available
Led By Cathleen M McCabe, MD
Research Sponsored by Cathleen McCabe MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days - iop measured at day 1, day 14 and day 30
Awards & highlights
Study Summary
This trial will help determine if MIGS is effective in reducing pressure in the eye for glaucoma patients who have also had cataract surgery.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days - iop measured at day 1, day 14 and day 30
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days - iop measured at day 1, day 14 and day 30
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Mean Intraocular Pressure from Baseline
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Dextenza 0.4mgExperimental Treatment1 Intervention
Intracanalicular insert
Group II: Durezol 0.05%Active Control1 Intervention
difluprednate ophthalmic emulsion
Find a Location
Who is running the clinical trial?
Cathleen McCabe MDLead Sponsor
Ocular Therapeutix, Inc.Industry Sponsor
53 Previous Clinical Trials
5,576 Total Patients Enrolled
14 Trials studying Cataract
1,970 Patients Enrolled for Cataract
Cathleen M McCabe, MDPrincipal InvestigatorThe Eye Associates of Manatee
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger